Daiwa Securities Group Inc. Purchases 9,364 Shares of Zai Lab Limited (NASDAQ:ZLAB)

Daiwa Securities Group Inc. grew its holdings in Zai Lab Limited (NASDAQ:ZLAB) by 4,851.8% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 9,557 shares of the company’s stock after purchasing an additional 9,364 shares during the period. Daiwa Securities Group Inc.’s holdings in Zai Lab were worth $231,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in ZLAB. Algert Global LLC acquired a new stake in Zai Lab in the 3rd quarter valued at $1,666,000. Connor Clark & Lunn Investment Management Ltd. grew its stake in Zai Lab by 26.2% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 604,153 shares of the company’s stock valued at $14,584,000 after purchasing an additional 125,532 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its position in shares of Zai Lab by 58.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,559 shares of the company’s stock worth $231,000 after purchasing an additional 3,514 shares during the last quarter. DekaBank Deutsche Girozentrale raised its stake in shares of Zai Lab by 22.2% during the 3rd quarter. DekaBank Deutsche Girozentrale now owns 36,648 shares of the company’s stock worth $899,000 after purchasing an additional 6,648 shares in the last quarter. Finally, Hennion & Walsh Asset Management Inc. boosted its holdings in shares of Zai Lab by 14.6% in the 3rd quarter. Hennion & Walsh Asset Management Inc. now owns 142,189 shares of the company’s stock valued at $3,432,000 after buying an additional 18,093 shares during the last quarter. Institutional investors own 41.65% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on ZLAB. Cantor Fitzgerald restated an “overweight” rating on shares of Zai Lab in a research note on Friday, October 25th. JPMorgan Chase & Co. boosted their target price on Zai Lab from $38.00 to $44.00 and gave the stock an “overweight” rating in a report on Monday, October 21st.

Zai Lab Stock Up 2.6 %

Zai Lab stock opened at $28.85 on Monday. Zai Lab Limited has a twelve month low of $13.48 and a twelve month high of $36.60. The stock has a market cap of $2.87 billion, a P/E ratio of -10.42 and a beta of 1.04. The company’s 50-day moving average price is $27.30 and its two-hundred day moving average price is $21.71.

Zai Lab Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.